Please wait while the formulary information is being retrieved.
COMETRIQ (CABOZANTINIB S-MALATE)
- Medullary thyroid carcinoma
100 mg/day (80 mg x 1-20 mg x 1) capsules
- Dosage information is not available
140 mg/day (80 mg x 1-20 mg x 3) capsules
- Dosage information is not available
60 mg/day (20 mg x 3/day) capsules
- 3 capsules (60 mg) by oral route once daily with water on an empty stomach at least 2 hours before or 1 hour after a meal
Medullary thyroid carcinoma
- 3 capsules (60 mg) by oral route once daily swallowing whole with water on an empty stomach at least 2 hours before or 1 hour after a meal
- 3 capsules (60 mg) by oral route once daily with water on an empty stomach at least 2 hours before or 1 hour after a meal
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- B cplx-C-St.Johnwrt-K.&S.ginsg
- BCG vaccine, live (PF)
- calcium-mag-B complex-D3-hrb61
- Cold & Flu Fighter
- Fatigue Relief Complex
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- St. John's wort
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- vit C-St. John wort-elder-hb30
- Vivotif Berna Vaccine
- Women's Complex
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- Belladonna-phenobarbital
- carbamazepine
- Carbatrol
- Cerebyx
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- enzalutamide
- Epitol
- Equetro
- fosphenytoin
- isoniazid-rifamp-pyrazinamide
- Luminal
- Mycobutin
- Mysoline
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- primidone
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Tegretol
- Tegretol Xr
- Xtandi
Severe
Moderate
- None
- Acute arterial thromboembolism
- Arterial aneurysm
- Arterial dissection
- Gastrointestinal hemorrhage
- Hemoptysis
- Lactating mother
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome
- Severe uncontrolled hypertension
- Thrombocytopenic disorder
Contraindicated
- Abnormal hepatic function tests
- Gastrointestinal fistula
- Gastrointestinal perforation
- Hypertension
- Impaired wound healing
- Neutropenic disorder
- Pregnancy
- Stomatitis
- Surgical wound dehiscence
- Thromboembolic disorder
- Tracheoesophageal fistula
- Venous thrombosis
Severe
Moderate
- Proteinuria
COMETRIQ (CABOZANTINIB S-MALATE)
- Medullary thyroid carcinoma
- Abnormal hepatic function tests
- Hyperbilirubinemia
- Hypocalcemia
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Lymphopenia
- Neutropenic disorder
- Palmar-plantar erythrodysesthesia
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Constipation
- Diarrhea
- Dysgeusia
- Fatigue
- General weakness
- Hair discoloration
- Headache disorder
- Hypertension
- Nausea
- Stomatitis
- Voice change
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Arterial thrombosis
- Aseptic necrosis of jaw bone
- Gastrointestinal fistula
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Hemoptysis
- Hemorrhage
- Hypokalemia
- Hyponatremia
- Impaired wound healing
- Tracheoesophageal fistula
- Venous thrombosis
- Alopecia
- Arthralgias
- Dizziness
- Dry skin
- Dyspepsia
- Dysphagia
- Erythema
- Hemorrhoids
- Hypotension
- Muscle spasm
- Non-cardiac chest pain
- Paresthesia
- Peripheral neuropathy
- Proteinuria
- Skin rash
- Symptoms of anxiety
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cholestatic hepatitis
- Nephrotic syndrome
- Pancreatitis
- Posterior reversible encephalopathy syndrome
Less Severe
- Hyperkeratosis
Contraindicated
None
Severe Precaution
Cabozantinib
Theoretical risk of adverse effects on bone marrow and organs. Safety and efficacy not established.
- 1 Day – 18 Years
- Theoretical risk of adverse effects on bone marrow and organs. Safety and efficacy not established.
Management or Monitoring Precaution
None
Cabozantinib
- Severity Level:
D
- Additional Notes: Insuff human data; based on pharmacology and animal data dev tox may occur
Contraindicated
Cabozantinib
Manufacturer recommends discontinuation of nursing due to potential risks
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Manufacturer recommends discontinuation of nursing due to potential risks |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Cabozantinib may rarely cause serious, possibly fatal, stomach/abdominal side effects such as a hole in the gut wall (perforation) or an abnormal tunnel or connection in your body (fistula). It can also rarely cause serious, possibly fatal, bleeding. Do not take this medication if you have serious bleeding. Get medical help right away if you have unusual or easy bruising/bleeding, signs of stomach/intestinal bleeding (such as bloody/black/tarry stools, stomach/abdominal pain, bloody vomit, vomit that looks like coffee grounds), fever, chills, severe vomiting/diarrhea, or if you are coughing/gagging/choking when eating or drinking, or coughing up blood.
| Medullary thyroid carcinoma | |
| C73 | Malignant neoplasm of thyroid gland |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| 0-9 | A-Z |
|---|---|
| C73 | Malignant neoplasm of thyroid gland |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
Formulary Reference Tool